Ezetimibe (Ezetrol)
Is It Right for You?
A complete guide to Ezetimibe (Ezetrol) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Ezetimibe (Ezetrol)?
Ezetimibe, marketed as Ezetrol, is a cholesterol absorption inhibitor available in tablets of 10 mg for once-daily dosing. It is used to lower low-density lipoprotein cholesterol (LDL-C) as an adjunct to statin therapy in patients who have not achieved their target LDL-C on statin treatment alone, or as monotherapy in patients who are intolerant of statins.
Ezetimibe works by a mechanism entirely distinct from statins — rather than inhibiting cholesterol synthesis in the liver, it blocks dietary and biliary cholesterol absorption from the small intestine. When added to a statin, ezetimibe provides additive LDL-C lowering of approximately 15–25%, addressing both the synthesis and absorption pathways simultaneously. The landmark IMPROVE-IT trial (2015) established that ezetimibe combined with simvastatin reduced cardiovascular events compared to simvastatin alone in patients following acute coronary syndromes — confirming that the LDL-C lowering achieved by ezetimibe translates into genuine cardiovascular risk reduction.
Ezetimibe is a prescription-only medication in the UK.
What Conditions Is Ezetimibe Used For?
Ezetimibe is indicated for:
for patients not achieving target LDL-C on maximum tolerated statin dose; ezetimibe provides meaningful additional LDL-C lowering without statin dose escalation
for patients with statin intolerance (myalgia, myopathy, or contraindication to statins) who require pharmacological LDL-C lowering
as part of combination lipid-lowering therapy (with statin and/or PCSK9 inhibitor) for this severe inherited condition
a rare inherited condition causing excessive absorption of plant sterols; ezetimibe blocks the NPC1L1 transporter that absorbs both cholesterol and plant sterols
Ezetimibe reduces LDL-C and has been shown to reduce cardiovascular events, but it does not eliminate cardiovascular risk. Its use is most effective as part of a comprehensive cardiovascular risk management strategy that includes statin therapy where tolerated, smoking cessation, blood pressure control, diabetes management, and lifestyle modification (diet, exercise, healthy weight).
How Does Ezetimibe Work?
Ezetimibe's lipid-lowering mechanism is mechanistically distinct from all other lipid-lowering agents, targeting the intestinal absorption of cholesterol rather than its hepatic synthesis:
NPC1L1 transporter inhibition: Dietary cholesterol and biliary cholesterol (secreted by the liver into the bile) are absorbed from the lumen of the small intestine into enterocytes (intestinal absorptive cells) primarily via the Niemann-Pick C1-Like 1 (NPC1L1) protein — a sterol transporter located on the brush border membrane of small intestinal enterocytes and hepatocytes. Ezetimibe selectively binds to and inhibits NPC1L1, blocking the transfer of cholesterol from the intestinal lumen into the enterocyte.
Reduction of intestinal cholesterol delivery to the liver: By blocking NPC1L1, ezetimibe reduces the amount of cholesterol delivered via chylomicron remnants to the liver by approximately 50%. In response to reduced cholesterol delivery, hepatocytes upregulate LDL receptor expression on their surface — increasing LDL particle uptake from the circulation and resulting in a fall in plasma LDL-C of approximately 15–25%.
Complementary mechanism with statins: Statins reduce hepatic cholesterol synthesis (by inhibiting HMG-CoA reductase), which prompts the liver to upregulate LDL receptors. However, the compensatory increase in intestinal cholesterol absorption that statins trigger — a physiological response to reduced hepatic cholesterol synthesis — is directly countered by ezetimibe. This mechanistic complementarity is why the combination of a statin with ezetimibe provides greater LDL-C reduction than doubling the statin dose.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Can be taken with or without food. Food has no significant effect on ezetimibe absorption.
Take at a consistent time each day. Once-daily dosing at any convenient time supports adherence; many patients find it easiest to take alongside other medications.
If also taking a bile acid sequestrant (colestyramine, colesevelam), take ezetimibe at least 2 hours before or 4 hours after the sequestrant, as bile acid resins significantly impair ezetimibe absorption.
Ezetimibe is typically taken alongside a statin. Both can be taken at the same time without any pharmacokinetic interaction. Alternatively, a fixed-dose combination tablet (Inegy — simvastatin/ezetimibe) is available for patients requiring the simvastatin and ezetimibe combination.
Lipid levels should be checked at baseline and approximately 6–12 weeks after initiating or changing ezetimibe therapy to assess response.
Side Effects of Ezetimibe
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Headache
- Diarrhoea and gastrointestinal discomfort --- mild; rarely require treatment discontinuation
- Fatigue
- Arthralgia (joint pain)
- Elevated liver enzymes --- uncommon at ezetimibe monotherapy doses; more common in combination with statins
- Myopathy and rhabdomyolysis --- rare with ezetimibe monotherapy; risk is increased in combination with statins; any new unexplained muscle pain, weakness, or tenderness requires prompt clinical assessment and CK measurement; dark urine may indicate rhabdomyolysis — seek emergency care
- Severe hepatotoxicity --- rare; jaundice, right upper quadrant pain, or markedly elevated liver enzymes require immediate clinical review
- Severe hypersensitivity reactions --- anaphylaxis, angioedema, urticaria; rare
- Pancreatitis --- rare case reports
Although ezetimibe monotherapy rarely causes myopathy, its combination with a statin carries a modestly increased myopathy risk compared to statin monotherapy. Any new unexplained muscle pain, cramps, or weakness in a patient on statin + ezetimibe therapy must be assessed promptly with creatine kinase (CK) measurement.
Drug Interactions
Always disclose all prescription drugs, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting Ezetimibe
ciclosporin significantly increases ezetimibe plasma exposure (AUC approximately 3.4-fold); increased risk of ezetimibe-related adverse effects; monitor closely; the combination requires careful clinical assessment.
combination with ezetimibe may increase ezetimibe plasma levels; gemfibrozil in particular approximately doubles ezetimibe exposure; increased cholesterol excretion into bile may increase cholelithiasis risk; use with caution.
additive monitoring is prudent when adding ezetimibe to warfarin; some reports of modest INR changes; monitor INR.
no clinically significant pharmacokinetic interaction between ezetimibe and statins; the combination is safe and well tolerated.
Important Warnings
Any new, unexplained muscle pain, weakness, or tenderness in a patient taking ezetimibe alongside a statin must be investigated promptly with creatine kinase measurement. Statin-associated myopathy risk is modestly increased by ezetimibe co-prescription. Rhabdomyolysis — though rare — is a medical emergency requiring urgent assessment.
Liver function tests should be performed at baseline and periodically during combination statin/ezetimibe therapy, particularly in patients with pre-existing hepatic disease. Ezetimibe is not recommended in patients with moderate or severe hepatic impairment.
The simultaneous administration of a bile acid sequestrant with ezetimibe dramatically reduces ezetimibe absorption. These agents must be separated by at least 2 hours if ezetimibe is taken before, or 4 hours if taken after the sequestrant.
Ezetimibe is contraindicated in pregnancy and breastfeeding. Cholesterol biosynthesis is essential for fetal development; lipid-lowering therapy carries a theoretical risk of fetal harm. Women of childbearing potential must use effective contraception during ezetimibe therapy. If pregnancy is confirmed, ezetimibe should be discontinued immediately.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Ezetimibe FAQs
Adding ezetimibe to a statin typically reduces LDL-C by an additional 15–25% — equivalent to the LDL-C lowering achieved by doubling the statin dose — but with a substantially better tolerability profile. Statin dose-doubling only provides a further 6% reduction in LDL-C (the "rule of sixes") while substantially increasing the risk of statin-associated side effects including myalgia. Adding ezetimibe is therefore a more effective and better-tolerated strategy for patients who have not achieved target LDL-C on their current statin dose.
Yes — the IMPROVE-IT trial (2015) demonstrated that adding ezetimibe to simvastatin in patients following acute coronary syndromes reduced the composite of major cardiovascular events by a statistically significant 6.4% relative reduction compared to simvastatin alone, over a median follow-up of 6 years. This established that ezetimibe's LDL-C lowering translates into genuine clinical cardiovascular benefit — not merely a favourable change in a laboratory number.
Yes — ezetimibe monotherapy is an appropriate lipid-lowering option for patients who cannot tolerate statins due to myalgia, myopathy, or other adverse effects. It provides LDL-C reduction of approximately 15–25% as monotherapy. While this is less than the reduction typically achieved with high-intensity statin therapy, it represents meaningful cardiovascular risk reduction in statin-intolerant patients. More potent non-statin alternatives include PCSK9 inhibitors (evolocumab, alirocumab) for very high-risk patients, used under specialist supervision.
Dietary modification targeting cholesterol intake complements ezetimibe's mechanism directly, as ezetimibe works by blocking intestinal cholesterol absorption. Reducing dietary saturated fat and cholesterol intake (limiting red meat, full-fat dairy, processed foods) and increasing soluble fibre (oats, pulses, fruit) provides additive LDL-C lowering. A heart-healthy diet, regular aerobic exercise, and healthy weight maintenance remain the foundation of cardiovascular risk management regardless of pharmacological therapy.
Yes — Inegy is a fixed-dose combination tablet containing ezetimibe 10 mg and simvastatin (in various doses: 10, 20, 40, or 80 mg). It delivers identical pharmacological components to taking ezetimibe and simvastatin as separate tablets, with the convenience of a single pill. The choice between a fixed combination (Inegy) and separate tablets (Ezetrol + simvastatin) is typically based on patient preference, prescribing convenience, and whether the required simvastatin dose is available in the combination product.